Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

Life Spine(R) Announces FDA Clearance Of FS3(TM) Minimally Invasive Spinal System
Life Spine announced today that the U.S. Food and Drug Administration (FDA) has given 510(k) marketing clearance to the FS3 Minimally Invasive Spinal System.
generic viagra online
Improve Communication With Your Healthcare Practitioner With The AGS Foundation For Health In Aging's New Health Tip Sheet
Good communication between patients and their healthcare practitioners is essential to good care. To help older adults better communicate with their healthcare providers, the American Geriatrics Society"s Foundation for Health in Aging (FHA) has released a new, easily understandable tip sheet for older people and their caregivers.
News of the day
American Pharmacists Association Seeks Nominations For Practitioner Awards And Honors
The American Pharmacists Association (APhA), the national professional society of pharmacists, announces that nominations are now being accepted for the Association"s practitioner awards and honors. Presentation of these awards is scheduled for the APhA Annual Meeting and Exposition in Washington, DC, March 12-15, 2010. Nominations must be received at APhA headquarters by September 15, 2009. APhA"s awards recognition program is American pharmacy"s most comprehensive recognition program.
Public Health

REGiMMUNE Presents Enhanced Efficacy Data In Preclinical Transplantation Models

Data presented at the 2009 American Transplant Congress REGiMMUNE Corporation has announced that its lead product candidate RGI-2001, in combination with a low-dose of Sirolimus, demonstrated enhanced efficacy in transplantation tolerance induction in models of skin transplantation and acute Graft-versus-Host disease (GvHD). This data was presented in a poster titled "Donor-Specific Tolerance Induction by a Liposomal Formulation of KRN7000 (RGI-2001) Alone and in Combination with Low-Dose Sirolimus" at the 2009 American Transplant Congress being held in Boston. "We are extremely pleased to present this data," stated Haru Morita, President and Chief Executive Officer of REGiMMUNE. "The study not only demonstrated the efficacy of RGI-2001 in solid organ transplants; it showed the potential of RGI-2001 to induce antigen-specific transplantation tolerance, which is considered a holy grail in transplantation." KRN7000, a synthetic derivative of alpha-galactosylceramide, is a small molecule that potently activates natural killer T (NKT) cells. RGI-2001 is a proprietary liposomal formulation of KRN7000. RGI-2001 monotherapy has shown to induce antigen-specific immune suppression by inducing regulatory T cells (Tregs). Tregs are believed to play a central role in inducing and maintaining immune tolerance. The study was designed to evaluate the efficacy of RGI-2001 in combination with Sirolimus in transplantation tolerance induction in mouse models. Study Results Pharmacological induction of alloantigen-specific tolerance is expected to provide significant clinical benefits in organ transplantation and bone marrow transplantation. The REGiMMUNE study concluded that the addition of a subtherapeutic dose of Sirolimus enhanced the efficacy of RGI-2001 in both models. The combination treatment significantly prolonged the survival of grafts in the skin transplant model over Sirolimus single treatment. Likewise, GvHD mortality was reduced by the combination treatment. In addition, the combination of RGI-2001 with low-dose Sirolimus significantly enhanced Treg induction. The results indicate the potential of RGI-2001 to be a key component of a novel tolerance induction regimen, avoiding the use of calcineurin inhibitors that are not only associated with high toxicity but suppress Treg activity. The finding suggests the possibility to develop a pharmacological approach to induce long-term transplant tolerance by promoting the body"s intrinsic tolerogenic pathways using RGI-2001. RGI-2001 is in late preclinical development and REGiMMUNE plans to file an Investigational New Drug (IND) for the prevention of acute GvHD associated with bone marrow transplantation later this year. Debra Bannister REGiMMUNE


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009